Annual CAPEX
$320.90 K
-$648.30 K-66.89%
31 December 2023
Summary:
Inovio Pharmaceuticals annual capital expenditures is currently $320.90 thousand, with the most recent change of -$648.30 thousand (-66.89%) on 31 December 2023. During the last 3 years, it has fallen by -$1.20 million (-78.90%). INO annual CAPEX is now -96.88% below its all-time high of $10.29 million, reached on 31 December 2017.INO CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
N/A
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly capital expenditures is not available.INO Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
N/A
30 September 2024
Summary:
Inovio Pharmaceuticals TTM capital expenditures is not available.INO TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -66.9% | - | - |
| 3 y3 years | -78.9% | - | - |
| 5 y5 years | -84.6% | - | - |
INO CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -78.9% | at low | ||||
| 5 y | 5 years | -84.6% | at low | ||||
| alltime | all time | -96.9% | +438.4% |
Inovio Pharmaceuticals CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $452.30 K(+1170.5%) | $487.90 K(+720.0%) |
| Mar 2024 | - | $35.60 K(>+9900.0%) | $59.50 K(-81.5%) |
| Dec 2023 | $320.90 K(-66.9%) | $0.00(0.0%) | $320.90 K(-34.0%) |
| Sept 2023 | - | $0.00(-100.0%) | $486.00 K(-15.2%) |
| June 2023 | - | $23.90 K(-92.0%) | $572.80 K(-54.8%) |
| Mar 2023 | - | $297.00 K(+79.9%) | $1.27 M(+30.6%) |
| Dec 2022 | $969.20 K(-21.3%) | $165.10 K(+90.2%) | $969.10 K(-33.1%) |
| Sept 2022 | - | $86.80 K(-87.9%) | $1.45 M(-5.3%) |
| June 2022 | - | $717.20 K(+11.4%) | $1.53 M(+24.2%) |
| Dec 2021 | $1.23 M(-19.1%) | $643.70 K(+281.8%) | $1.23 M(-20.5%) |
| Sept 2021 | - | $168.60 K(-18.9%) | $1.55 M(-12.1%) |
| June 2021 | - | $207.90 K(-1.4%) | $1.76 M(+10.8%) |
| Mar 2021 | - | $210.80 K(-78.1%) | $1.59 M(+4.6%) |
| Dec 2020 | $1.52 M(+53.9%) | $962.10 K(+151.8%) | $1.52 M(+125.9%) |
| Sept 2020 | - | $382.10 K(+973.3%) | $673.10 K(+58.5%) |
| June 2020 | - | $35.60 K(-74.8%) | $424.70 K(-9.7%) |
| Mar 2020 | - | $141.00 K(+23.3%) | $470.20 K(-52.4%) |
| Dec 2019 | $987.90 K(-52.6%) | $114.40 K(-14.4%) | $987.90 K(-18.8%) |
| Sept 2019 | - | $133.70 K(+64.9%) | $1.22 M(+0.5%) |
| June 2019 | - | $81.10 K(-87.7%) | $1.21 M(-23.9%) |
| Mar 2019 | - | $658.70 K(+92.0%) | $1.59 M(-23.7%) |
| Dec 2018 | $2.08 M(-79.7%) | $343.10 K(+169.7%) | $2.09 M(-20.4%) |
| Sept 2018 | - | $127.20 K(-72.4%) | $2.62 M(-56.9%) |
| June 2018 | - | $461.30 K(-60.0%) | $6.08 M(-42.9%) |
| Mar 2018 | - | $1.15 M(+31.4%) | $10.66 M(+3.5%) |
| Dec 2017 | $10.29 M(+161.4%) | $878.10 K(-75.5%) | $10.29 M(+8.6%) |
| Sept 2017 | - | $3.59 M(-28.8%) | $9.48 M(+48.9%) |
| June 2017 | - | $5.04 M(+538.4%) | $6.37 M(+57.4%) |
| Mar 2017 | - | $789.30 K(+1092.3%) | $4.05 M(+2.7%) |
| Dec 2016 | $3.94 M(+41.6%) | $66.20 K(-86.1%) | $3.94 M(-16.2%) |
| Sept 2016 | - | $475.30 K(-82.5%) | $4.70 M(-6.1%) |
| June 2016 | - | $2.72 M(+298.7%) | $5.01 M(+70.5%) |
| Mar 2016 | - | $681.10 K(-17.5%) | $2.94 M(+5.5%) |
| Dec 2015 | $2.78 M(+101.6%) | $825.90 K(+5.5%) | $2.78 M(+30.7%) |
| Sept 2015 | - | $782.60 K(+21.1%) | $2.13 M(+27.7%) |
| June 2015 | - | $646.20 K(+22.6%) | $1.67 M(-3.4%) |
| Mar 2015 | - | $526.90 K(+206.2%) | $1.73 M(+25.0%) |
| Dec 2014 | $1.38 M(+680.1%) | $172.10 K(-46.3%) | $1.38 M(+21.7%) |
| Sept 2014 | - | $320.70 K(-54.5%) | $1.13 M(+13.6%) |
| June 2014 | - | $705.40 K(+288.0%) | $998.00 K(+212.9%) |
| Mar 2014 | - | $181.80 K(-346.7%) | $319.00 K(+80.3%) |
| Dec 2013 | $176.90 K(-26.6%) | -$73.70 K(-139.9%) | $176.90 K(-34.9%) |
| Sept 2013 | - | $184.50 K(+598.9%) | $271.70 K(+161.0%) |
| June 2013 | - | $26.40 K(-33.5%) | $104.10 K(-43.5%) |
| Mar 2013 | - | $39.70 K(+88.2%) | $184.30 K(-23.5%) |
| Dec 2012 | $241.00 K | $21.10 K(+24.9%) | $240.90 K(-9.8%) |
| Sept 2012 | - | $16.90 K(-84.1%) | $267.00 K(-0.4%) |
| June 2012 | - | $106.60 K(+10.7%) | $268.10 K(+35.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $96.30 K(+104.0%) | $197.70 K(+22.6%) |
| Dec 2011 | $161.20 K(-47.4%) | $47.20 K(+162.2%) | $161.20 K(+15.8%) |
| Sept 2011 | - | $18.00 K(-50.3%) | $139.20 K(-4.1%) |
| June 2011 | - | $36.20 K(-39.5%) | $145.20 K(-55.8%) |
| Mar 2011 | - | $59.80 K(+137.3%) | $328.70 K(+7.2%) |
| Dec 2010 | $306.60 K(+85.9%) | $25.20 K(+5.0%) | $306.70 K(-2.7%) |
| Sept 2010 | - | $24.00 K(-89.1%) | $315.10 K(+6.6%) |
| June 2010 | - | $219.70 K(+481.2%) | $295.60 K(+112.4%) |
| Mar 2010 | - | $37.80 K(+12.5%) | $139.20 K(-15.6%) |
| Dec 2009 | $164.90 K(-71.8%) | $33.60 K(+646.7%) | $164.90 K(-29.7%) |
| Sept 2009 | - | $4500.00(-92.9%) | $234.70 K(-48.3%) |
| June 2009 | - | $63.30 K(-0.3%) | $453.60 K(-15.8%) |
| Mar 2009 | - | $63.50 K(-38.6%) | $539.00 K(-7.7%) |
| Dec 2008 | $583.80 K(-9.6%) | $103.40 K(-53.7%) | $583.70 K(-4.6%) |
| Sept 2008 | - | $223.40 K(+50.2%) | $611.70 K(+18.5%) |
| June 2008 | - | $148.70 K(+37.4%) | $516.40 K(+4.1%) |
| Mar 2008 | - | $108.20 K(-17.7%) | $496.10 K(-23.2%) |
| Dec 2007 | $645.70 K(-52.7%) | $131.40 K(+2.6%) | $645.80 K(-49.9%) |
| Sept 2007 | - | $128.10 K(-0.2%) | $1.29 M(-3.6%) |
| June 2007 | - | $128.40 K(-50.2%) | $1.34 M(-11.0%) |
| Mar 2007 | - | $257.90 K(-66.7%) | $1.50 M(+9.9%) |
| Dec 2006 | $1.37 M(+375.8%) | $773.90 K(+340.2%) | $1.37 M(+129.1%) |
| Sept 2006 | - | $175.80 K(-40.0%) | $596.00 K(+27.6%) |
| June 2006 | - | $292.80 K(+138.6%) | $467.20 K(+143.3%) |
| Mar 2006 | - | $122.70 K(+2510.6%) | $192.00 K(-33.1%) |
| Dec 2005 | $286.90 K(+180.2%) | $4700.00(-90.0%) | $286.90 K(-5.6%) |
| Sept 2005 | - | $47.00 K(+167.0%) | $303.80 K(+3.3%) |
| June 2005 | - | $17.60 K(-91.9%) | $294.00 K(-7.1%) |
| Mar 2005 | - | $217.60 K(+907.4%) | $316.50 K(+209.4%) |
| Dec 2004 | $102.40 K(+71.8%) | $21.60 K(-41.9%) | $102.30 K(-4.1%) |
| Sept 2004 | - | $37.20 K(-7.2%) | $106.70 K(+3.5%) |
| June 2004 | - | $40.10 K(+1079.4%) | $103.10 K(+63.7%) |
| Mar 2004 | - | $3400.00(-86.9%) | $63.00 K(+5.7%) |
| Dec 2003 | $59.60 K(-85.4%) | $26.00 K(-22.6%) | $59.60 K(-86.5%) |
| Sept 2003 | - | $33.60 K(-91.8%) | $441.20 K(+8.0%) |
| Dec 2002 | $408.70 K(+19.9%) | $407.60 K(>+9900.0%) | $408.70 K(>+9900.0%) |
| Sept 2002 | - | $1100.00(>+9900.0%) | $1100.00(-99.0%) |
| Dec 2001 | $341.00 K(+42.7%) | - | - |
| Sept 2001 | - | $0.00(-100.0%) | $113.10 K(-39.2%) |
| June 2001 | - | $29.20 K(-41.5%) | $185.90 K(-22.2%) |
| Mar 2001 | - | $49.90 K(+46.8%) | $238.90 K(-36.9%) |
| Mar 2001 | $239.00 K(-17.4%) | - | - |
| Dec 2000 | - | $34.00 K(-53.3%) | $378.50 K(-14.8%) |
| Sept 2000 | - | $72.80 K(-11.4%) | $444.50 K(+19.6%) |
| June 2000 | - | $82.20 K(-56.6%) | $371.70 K(+28.4%) |
| Mar 2000 | $289.50 K(-42.1%) | $189.50 K(+89.5%) | $289.50 K(+189.5%) |
| Dec 1999 | - | $100.00 K | $100.00 K |
| Mar 1999 | $500.00 K | - | - |
FAQ
- What is Inovio Pharmaceuticals annual capital expenditures?
- What is the all time high annual CAPEX for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual CAPEX year-on-year change?
- What is the all time high quarterly CAPEX for Inovio Pharmaceuticals?
- What is the all time high TTM CAPEX for Inovio Pharmaceuticals?
What is Inovio Pharmaceuticals annual capital expenditures?
The current annual CAPEX of INO is $320.90 K
What is the all time high annual CAPEX for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual capital expenditures is $10.29 M
What is Inovio Pharmaceuticals annual CAPEX year-on-year change?
Over the past year, INO annual capital expenditures has changed by -$648.30 K (-66.89%)
What is the all time high quarterly CAPEX for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly capital expenditures is $5.04 M
What is the all time high TTM CAPEX for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM capital expenditures is $10.66 M